The transmembrane protein HER2 is overexpressed in approximately 30% of breast cancer patients.HER2-positive breast cancers tend to spread more aggressively, which result in increased mortality inwomen. Nowadays, the ...The transmembrane protein HER2 is overexpressed in approximately 30% of breast cancer patients.HER2-positive breast cancers tend to spread more aggressively, which result in increased mortality inwomen. Nowadays, the real-time monitoring of HER2 status is important in clinical diagnosis andtreatment for HER2-positive patients. Although IHC and FISH assay are standard methods to evaluate thetissue HER2 status, both approaches which required high quality tissue samples and are not suitable formonitoring the status of HER2 in real time. Since extracellular domain （ECD） of the HER2 receptor can beshed into the circulation, the serum test of HER2 ECD has been developed as an additional approach toprobe HER2 overexpression. The serum test will be able to monitor the dynamic changes of HER2 status.In this paper, we detected serum HER2 ECD using CyS-labeled HB5 aptamer as a result of its specificbinding ability to HER2 ECD. This aptamer-based fluorescent probe is easily synthesized and modifiedand as sensitive as anti-HER2 antibodies. We believe that Cy5-HB5 may have application potentials inserum HER2 test for clinical utility of breast cancer, such as recurrence and metastases.展开更多
基金financially supported by the National Natural Science Foundation of China(Nos.81772812,21422606,21402191,and 21502189)Dalian Cultivation Fund for Distinguished Young Scholars(Nos.2014J11JH130 and 2015J12JH205)the Foundation of Dalian Science Department(No.2015E12SF149)
文摘The transmembrane protein HER2 is overexpressed in approximately 30% of breast cancer patients.HER2-positive breast cancers tend to spread more aggressively, which result in increased mortality inwomen. Nowadays, the real-time monitoring of HER2 status is important in clinical diagnosis andtreatment for HER2-positive patients. Although IHC and FISH assay are standard methods to evaluate thetissue HER2 status, both approaches which required high quality tissue samples and are not suitable formonitoring the status of HER2 in real time. Since extracellular domain （ECD） of the HER2 receptor can beshed into the circulation, the serum test of HER2 ECD has been developed as an additional approach toprobe HER2 overexpression. The serum test will be able to monitor the dynamic changes of HER2 status.In this paper, we detected serum HER2 ECD using CyS-labeled HB5 aptamer as a result of its specificbinding ability to HER2 ECD. This aptamer-based fluorescent probe is easily synthesized and modifiedand as sensitive as anti-HER2 antibodies. We believe that Cy5-HB5 may have application potentials inserum HER2 test for clinical utility of breast cancer, such as recurrence and metastases.
